

Exploring ternary copper coordination compounds interacting with DNA as a promising anticancer and antibacterial drug

I. Kekez¹, K. Mišković Špoljarić², D. Vušak¹, M. Belas¹, D. Kučera-Čavara¹, B. Prugovečki¹

¹University of Zagreb, Faculty of Science, Department of Chemistry, Horvatovac 102a, 10000 Zagreb, Croatia, ²University Josip Juraj Strossmayer Osijek, Faculty of Medicine, Josipa Huttlera 4, 31000 Osijek, Croatia

ikekez@chem.pmf.hr

Ternary metal complexes are gaining increasing attention in drug discovery due to their unique structural and biological properties [1-2]. These complexes feature a central metal ion coordinated by two distinct ligands, often resulting in enhanced stability, selectivity, and therapeutic potential. Among them, copper(II) coordination compounds with amino acidates and heterocyclic bases form a well-studied subclass known as Cassiopeia, recognized for their anticancer activity [3]. We have recently been involved in synthesizing novel copper ternary coordination compounds with different amino acids and heterocyclic bases, including 2,2'-bipyridine and 1,10-phenanthroline, as potential DNA binders with antiproliferative activity towards various cancer cells [4-5]. In this work, we have investigated anticancer activity of three different copper(II) ternary coordination compounds with glycine and 1,10-phenanthroline (**1** - $[\text{Cu}(\text{Gly})(\text{H}_2\text{O})(\text{phen})][\text{Cu}(\mu\text{-Gly})(\text{phen})]\text{SO}_4 \cdot 2\text{H}_2\text{O}$), **2** - $[\text{Cu}(\text{Gly})(\text{H}_2\text{O})(\text{phen})][\text{Cu}(\text{Gly})(\text{SO}_4)(\text{phen})] \cdot 5\text{H}_2\text{O}$ and **3** - $[\text{Cu}(\text{Gly})(\text{phen})(\text{H}_2\text{O})]_2\text{SO}_4 \cdot 6\text{H}_2\text{O}$). All three compounds (**1–3**) exhibited potent antiproliferative activity against five human cancer cell lines MDA-MB 231 (breast), Hep-G2 (liver), KATO III (gastric), PANC-1 (pancreatic duct) and Caco-2 (intestinal) with IC_{50} values ranging from 0.6 to 2.8 $\mu\text{mol dm}^{-3}$. The most potent and selective activity was observed against KATO III gastric cancer cells ($IC_{50} = 0.6 \mu\text{mol dm}^{-3}$), with lower cytotoxicity against MRC-5 healthy fibroblast control cells ($IC_{50} = 4 \mu\text{mol dm}^{-3}$). The antibacterial activity of compound **2** was also assessed against two Gram-positive (*S. aureus* ATCC 29213, *E. faecalis* ATCC 29212) and two Gram-negative strains (*E. coli* ToIC-Tn10, *M. catarrhalis* ATCC 23246). It displayed moderate activity against Gram-positive bacteria and pronounced activity against Gram-negative strains, with the lowest minimal inhibitory concentration (MIC) observed for *M. catarrhalis* (MIC = 4 $\mu\text{g/mL}$). The binding affinity of compound **2** toward the double-stranded oligonucleotide DNA (ds(CGCGAATTCGCG)) was explored by spectroscopic and crystallographic methods. Absorption and fluorescence spectra suggested a moderate binding affinity of **2** to the double-stranded DNA dodecamer. Co-crystallization experiments were carried out using the Oryx8 crystallization robot, and obtained crystals were further analysed using the X-ray diffraction method on XRD2 Elettra synchrotron beamline (Trieste, Italy). A new crystal form of double-stranded DNA dodecamer ds(CGCGAATTCGCG) was obtained, crystallizing in trigonal space group – *H3* with unit cell parameters $a = b = 38.520 \text{ \AA}$, $c = 99.200 \text{ \AA}$, $\alpha = \beta = 90^\circ$, $\gamma = 120^\circ$. These findings highlight the potential of copper-based ternary complexes as dual-function anticancer and antibacterial agents. Their capacity to engage with DNA and exhibit selective biological activity positions them as promising candidates in the development of next-generation metallodrugs.

- [1] Zhang, Z., Wang, H., Wang Q., Yan, M., Wang, H., Bi, C., Sun, S. & Fan, Y. (2016). *Int. J. Oncol.* **49**(2), 691–699.
- [2] Rajeshwari, K., Vasantha, P., Sathish Kumar, B. & Anantha Lakshmi, P. V. (2022). *Biol. Trace Elem. Res.* **200**, 5351-5364.
- [3] Bravo-Gómez, M. E., García-Ramos, J.C., Gracia-Mora, I. & Ruiz-Azuara L. (2009). *J. Inorg. Biochem.* **103**(2), 299-309.
- [4] Vušak, D., Ležaić, K., Jurec, J., Žilić, D. & Prugovečki, B. (2022). *Heliyon* **8**(6), e09556.
- [5] Vušak, D., Šimunović Letić, M., Tašner, M., Matković-Čalogović, D., Jurec, J., Žilić, D. & Prugovečki, B. (2024). *Molecules* **29**(23), 5621.